Impaired hypothalamic insulin signaling in CUMS rats: Restored by icariin and fluoxetine through inhibiting CRF system

Psychoneuroendocrinology

Volumn 38, Issue 1, 2013, Pages 122-134

  Pan, Ying ^a   Hong, Ye ^a   Zhang, Qing Yu ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Chronic unpredictable mild stress; Fluoxetine; Hypothalamic corticotropin releasing factor system; Icariin; Insulin signaling

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; FLUOXETINE; ICARIIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTYROSINE; PIOGLITAZONE; SUPPRESSOR OF CYTOKINE SIGNALING 3; UROCORTIN II;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARCUATE NUCLEUS; ARTICLE; CHRONIC UNPREDICTABLE MILD STRESS; CYTOKINE PRODUCTION; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENE SEQUENCE; GLUCOSE INTOLERANCE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STRESS; TREATMENT DURATION; TREATMENT RESPONSE;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; ARCUATE NUCLEUS; CHRONIC DISEASE; CORTICOTROPIN-RELEASING HORMONE; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FLAVONOIDS; FLUOXETINE; GENE EXPRESSION REGULATION; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THIAZOLIDINEDIONES; UP-REGULATION; UROCORTINS;

EID: 84870390822     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.05.007     Document Type: Article

References (58)

1. Ahmad F., Lindh R., Tang Y., Weston M., Degerman E., Manganiello V.C. Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem. J. 2007, 404:257-268.
2. Akabayashi A., Zaia C.T., Gabriel S.M., Silva I., Cheung W.K., Leibowitz S.F. Intracerebroventricular injection of dibutyryl cyclic adenosine 3',5'-monophosphate increases hypothalamic levels of neuropeptide Y. Brain Res. 1994, 660:323-328.
3. Ambrogio A.G., Pecori Giraldi F., Cavagnini F. Drugs and HPA axis. Pituitary 2008, 11:219-229.
4. Auernhammer C.J., Melmed S. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J. Clin. Invest. 2001, 108:1735-1740.
5. Bale T.L., Anderson K.R., Roberts A.J., Lee K.F., Nagy T.R., Vale W.W. Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 2003, 144:2580-2587.
6. Bates S.H., Stearns W.H., Dundon T.A., Schubert M., Tso A.W.K., Wang Y., Banks A.S., Lavery H.J., Haq A.K., Maratos-Flier E., Neel B.G., Schwartz M.W., Myers M.G. STAT3 signaling is required for leptin regulation of energy balance but not reproduction. Nature 2003, 421:856-859.
7. Brar B.K., Chen A., Perrin M.H., Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 2004, 145:1718-1729.
8. Butterweck V., Winterhoff H., Herkenham M. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol. Psychiatry 2001, 6:547-564.
9. Caberlotto L., Fuxe K., Overstreet D.H., Gerrard P., Hurd Y.L. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Mol. Brain Res. 1998, 59:58-65.
10. Campayo A., de Jonge P., Roy J.F., Saz P., de la Camara C., Quintanilla M.A., Marcos G., Santabarbara J., Lobo A. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am. J. Psychiatry 2010, 167:580-588.
11. Carvalheira J.B., Siloto R.M., Ignacchitti I., Brenelli S.L., Carvalho C.R., Leite A., Velloso L.A., Gontijo J.A., Saad M.J. Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett. 2001, 500:119-124.
12. Carvalheira J.B.C., Torsoni M.A., Ueno M., Amaral M.E., Araujo E.P., Velloso L.A., Gontijo J.A.R., Saad M.J.A. Cross-talk between the insulin and leptin signaling systems in rat hypothalamus. Obes. Res. 2005, 13:48-57.
13. Chen A., Brar B., Choi C.S., Rousso D., Vaughan J., Kuperman Y., Kim S.N., Donaldson C., Smith S.M., Jamieson P., Li C., Nagy T.R., Shulman G.I., Lee K.F., Vale W. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16580-16585.
14. Chen, A.M., Lee, K.F., Li, C., Vale, W.W., 2010a, Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors. US Patent 7,815,905.
15. Chen J., Evans A.N., Liu Y., Honda M., Saavedra J.M., Aguilera G. Maternal deprivation in rats is associated with corticotropin releasing hormone (CRH) promoter hypomethylation and enhances CRH transcriptional responses to stress in adulthood. J. Neuroendocrinol. 2012, 10.1111/j.1365-2826.2012.02306.x.
16. Chen P., Vaughan J., Donaldson C., Vale W., Li C. Injection of urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis. Am. J. Physiol. Endocrinol. Metab. 2010, 298:337-345.
17. Garcia-Diaz D.F., Campion J., Milagro F.I., Lomba A., Marzo F., Martinez J.A. Chronic mild stress induces variations in locomotive behavior and metabolic rates in high fat fed rats. J. Physiol. Biochem. 2007, 63:337-346.
18. Golden S.H. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Curr. Diabetes Rev. 2007, 3:252-259.
19. Goodnick P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry 2001, 13:31-41.
20. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 2006, 5:453-479.
21. Hauger R.L., Risbrough V., Oakley R.H., Olivares-Reyes J.A., Dautzenberg F.M. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann. N.Y. Acad. Sci. 2009, 1179:120-143.
22. Henry B., Vale W., Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J. Neurosci. 2006, 26:9142-9152.
23. Khazaie H., Rahimi M., Tatari F., Rezaei M., Najafi F., Tahmasian M. Treatment of depression in type 2 diabetes with fluoxetine or citalopram?. Neurosciences 2011, 16:42-45.
24. Kioukia-Fougia N., Antoniou K., Bekris S., Liapi C., Christofidis I., Papadopoulou-Daifoti Z. The effects of stress exposure on the hypothalamic-pituitary-adrenal axis, thymus, thyroid hormones and glucose levels. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2002, 26:823-830.
25. Kyrou I., Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 2009, 9:787-793.
26. Lerner R.G., Depatie C., Rutter G.A., Screaton R.A., Balthasar N. A role for the CREB co-activator CRTC2 in the hypothalamic mechanisms linking glucose sensing with gene regulation. EMBO Rep. 2009, 10:1175-1181.
27. Li J.M., Li Y.C., Kong L.D., Hu Q.H. Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology 2010, 51:1555-1566.
28. Lustman P.J., Freedland K.E., Griffith L.S., Clouse R.E. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000, 23:618-623.
29. Maheux P., Ducros F., Bourque J., Garon J., Chiasson J.L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int. J. Obes. 1997, 21:97-102.
30. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 2006, 26:6643-6650.
31. Mattioli L., Funari C., Perfumi M. Effects of Rhodiola rosea L. extract on behavioural and physiological alterations induced by chronic mild stress in female rats. J. Psychopharmacol. 2009, 23:130-142.
32. Mirshamsi S., Laidlaw H.A., Ning K., Anderson E., Burgess L.A., Gray A., Sutherland C., Ashford M.L.J. Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci. 2004, 5:54.
33. Mu X.C., Li D.Z. Epimedium treatment of diabetes and its complications. J. Tradit. Chin. Med. 2000, 41:10.
34. Niswender K.D., Morrison C.D., Clegg D.J., Olson R., Baskin D.G., Myers M.G., Seeley R.J., Schwartz M.W. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 2003, 52:227-231.
35. O'Kane M., Wiles P., Wales J. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet. Med. 1994, 11:105-110.
36. Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 2002, 8:1376-1382.
37. Pan W., Tu H., Hsuchou H., Daniel J., Kastin A.J. Unexpected amplification of leptin-induced Stat3 signaling by urocortin: implications for obesity. J. Mol. Neurosci. 2007, 33:232-238.
38. Pan Y., Zhang W.Y., Xia X., Kong L.D. Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol. Pharm. Bull. 2006, 29:2399-2403.
39. Pan Y., Wang F.M., Qiang L.Q., Zhang D.M., Kong L.D. Icariin attenuates chronic mild stress-induced dysregulation of the LHPA stress circuit in rats. Psychoneuroendocrinology 2010, 35:272-283.
40. Pan Y., Kong L.D., Li Y.C., Xia X., Kung H.F., Jiang F.X. Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. Pharmacol. Biochem. Behav. 2007, 87:130-140.
41. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004, 25:659-666.
42. Pocai A., Lam T.K.T., Gutierrez-Juarez R., Obici S., Schwartz G.J., Bryan J., Aguilar-Bryan L., Rossetti L. Hypothalamic K-ATP channels control hepatic glucose production. Nature 2005, 434:1026-1031.
43. Porte D. Central regulation of energy homeostasis-the key role of insulin. Diabetes 2006, 55:S155-S160.
44. Porte D., Baskin D.G., Schwartz M.W. Leptin and insulin action in the central nervous system. Nutr. Rev. 2002, 60:S20-S29. discussion S68-S84, 85-27.
45. Qi M.Y., Kai C., Liu H.R., Su Y.H., Yu S.Q. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor beta1 and type IV collagen expression in rats. J. Ethnopharmacol. 2011, 138:731-736.
46. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2002, 2:23-33.
47. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2843-2848.
48. Rubin R.R., Ma Y., Marrero D.G., Peyrot M., Barrett-Connor E.L., Kahn S.E., Haffner S.M., Price D.W., Knowler W.C., Diabetes Prevention Program Research Group Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008, 31:420-426.
49. Sahu A. Intracellular leptin-signaling pathways in hypothalamic neurons: the emerging role of phosphatidylinositol-3 Kinase-phosphodiesterase-3B-cAMP Pathway. Neuroendocrinology 2011, 93:201-210.
50. Sashinami H., Kageyama K., Suda T., Nakane A. Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via up-regulation of interleukin-10. Endocrinology 2005, 146:5003-5011.
51. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
52. Sergeyev V., Fetissov S., Mathe A.A., Jimenez P.A., Bartfai T., Mortas P., Gaudet L., Moreau J.L., Hokfelt T. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berl) 2005, 178:115-124.
53. Staub D.R., Spiga F., Lowry C.A. Urocortin 2 increases c-Fos expression in topographically organized subpopulations of serotonergic neurons in the rat dorsal raphe nucleus. Brain Res. 2005, 1044:176-189.
54. Suri D., Weiss R.E. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J. Clin. Endocrinol. Metab. 2005, 90:1340-1346.
55. Tanaka M., Telegdy G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull. 2008, 75:509-512.
56. Ueki K., Kondo T., Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 2004, 24:5434-5446.
57. Wang L.H., Zhou X.M., Ma Y.K., Cao Y.L., Fang J. Effect of epimedium hypoglycemic granules on type 2 diabetes rats and its mechanism. Shen Yang Yao Ke Da Xue Xue Bao 2005, 22:301-305.
58. Xin H., Zhou F., Liu T., Li G.Y., Liu J., Gao Z.Z., Bai G.Y., Lu H., Xin Z.C. Icariin ameliorates streptozotocin-induced diabetic retinopathy in vitro and in vivo. Int. J. Mol. Sci. 2012, 13:866-878.